Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.

about

Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.

Item

http://www.wikidata.org/entity/Q38700489

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Risk of peripheral edema in ca ...... a-analysis of clinical trials.

@en

type

Item

label

Risk of peripheral edema in ca ...... a-analysis of clinical trials.

@en

prefLabel

Risk of peripheral edema in ca ...... a-analysis of clinical trials.

@en

P1476

Risk of peripheral edema in ca ...... a-analysis of clinical trials.

@en

P2093

Guo-Wang Yang

http://www.w3.org/2001/XMLSchema#string

Lin Yang

http://www.w3.org/2001/XMLSchema#string

Ming-Wei Yu

http://www.w3.org/2001/XMLSchema#string

Pei-Yu Cheng

http://www.w3.org/2001/XMLSchema#string

Xiao-Min Wang

http://www.w3.org/2001/XMLSchema#string

Xu Sun

http://www.w3.org/2001/XMLSchema#string

Yi-Hua Liu

http://www.w3.org/2001/XMLSchema#string

Yong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Targeting the extracellular signal-regulated kinase pathway in cancer therapy

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Mutations of the BRAF gene in human cancer

Mammalian MAP kinase signalling cascades

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

P304

1663-1675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/03007995.2017.1349657

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28665153

http://www.w3.org/2001/XMLSchema#string